1215 related articles for article (PubMed ID: 34486707)
21. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
[TBL] [Abstract][Full Text] [Related]
22. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ
Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896
[TBL] [Abstract][Full Text] [Related]
23. Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.
Jordan K; Gralla R; Rizzi G; Kashef K
Support Care Cancer; 2016 Nov; 24(11):4617-25. PubMed ID: 27334131
[TBL] [Abstract][Full Text] [Related]
24. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Navari RM
Drug Des Devel Ther; 2015; 9():155-61. PubMed ID: 25552904
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R-CHOP chemotherapy.
Kwak K; Park Y; Kim BS; Kang KW
Sci Rep; 2024 May; 14(1):11229. PubMed ID: 38755279
[TBL] [Abstract][Full Text] [Related]
26. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Gralla RJ; Bosnjak SM; Hontsa A; Balser C; Rizzi G; Rossi G; Borroni ME; Jordan K
Ann Oncol; 2014 Jul; 25(7):1333-1339. PubMed ID: 24631949
[TBL] [Abstract][Full Text] [Related]
27. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
Hesketh PJ; Rossi G; Rizzi G; Palmas M; Alyasova A; Bondarenko I; Lisyanskaya A; Gralla RJ
Ann Oncol; 2014 Jul; 25(7):1340-1346. PubMed ID: 24608196
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients.
Aapro M; Jordan K; Gralla RJ; Rizzi G; Rossi G; Palmas M; Alyasova AV; Lisyanskaya AS; Bošnjak SM; Hesketh PJ
J Geriatr Oncol; 2017 Jan; 8(1):56-63. PubMed ID: 27889278
[TBL] [Abstract][Full Text] [Related]
30. Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life.
Karthaus M; Oskay-Özcelik G; Wülfing P; Hielscher C; Guth D; Zahn MO; Flahaut E; Schilling J
Future Oncol; 2020 May; 16(14):939-953. PubMed ID: 32298187
[No Abstract] [Full Text] [Related]
31. Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
Aapro M; Jordan K; Scotté F; Celio L; Karthaus M; Roeland E
Curr Cancer Drug Targets; 2022; 22(10):806-824. PubMed ID: 35570542
[TBL] [Abstract][Full Text] [Related]
32. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Rojas C; Slusher BS
Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
[TBL] [Abstract][Full Text] [Related]
34. Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment.
Giuliani J; Bonetti A
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):505-508. PubMed ID: 31379219
[No Abstract] [Full Text] [Related]
35. Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA).
Lorusso V; Russo A; Giotta F; Codega P
Core Evid; 2020; 15():21-29. PubMed ID: 32802009
[TBL] [Abstract][Full Text] [Related]
36. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.
Aapro M; Zhang L; Yennu S; LeBlanc TW; Schwartzberg L
Future Oncol; 2019 Apr; 15(10):1067-1084. PubMed ID: 30860400
[TBL] [Abstract][Full Text] [Related]
37. Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Keating GM
Drugs; 2015 Dec; 75(18):2131-41. PubMed ID: 26613606
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
[TBL] [Abstract][Full Text] [Related]
39. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.
Loteta B; Paviglianiti A; Naso V; Ferreri A; Moscato T; Console G; Canale FA; Irrera G; Pugliese M; Di Costanzo A; Provenzano PF; Loddo V; Porto G; Cusumano G; Russo L; Meliambro N; Romeo V; Porcino D; Gallo S; Gangemi T; Rossetti AM; Martino M
Support Care Cancer; 2022 Jan; 30(1):585-591. PubMed ID: 34347181
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]